EQT in Advanced Talks to Buy Qiagen With Binding Offer Above $50/Share
QGEN sits 52% above its 52-week low of $32.53 on elevated volume (2.3× avg).
Summary
EQT has moved from interest to a binding offer of more than $50 a share for Qiagen and is in advanced talks, per Bloomberg. That is a premium to the $49.30 price and puts a concrete floor under the takeover story that until now was only speculation. The timeline shows the process widening: TPG and Bain joined the list of interested PE firms in mid-September, and this is the first named bidder with a binding number. Qiagen also just installed Jonathan Pratt as CEO on September 1 and reaffirmed guidance, so the board is negotiating from a position of stable operations. A deal at this level would reprice the whole company; the key question now is whether the board engages or holds out for more.
At the time of this announcement, QGEN was trading at $49.30 on NYSE in the Life Sciences sector, with a market capitalization of approximately $10.2B. The 52-week trading range was $32.53 to $57.82. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.